ATOS

Atossa Therapeutics Inc

2.40

Oct 28 • 3:18 PM ET +0.02 (0.84%)

Healthcare Biotechnology USA Nano NASD

Peers: LONA OLMA CELC BCTX PBYI GLSI CNTX ANIX VERU ENSC

Index	-
Market Cap	23.95M
Enterprise Value	-2.25M
Income	-37.71M
Sales	0.00M
Book/sh	2.69
Cash/sh	2.63
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Nov 08, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.89
P/C	0.91
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.69
Current Ratio	5.69
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-4.34
EPS next Y	-2.78
EPS next Q	-0.86
EPS this Y	7.26%
EPS next Y	25.71%
EPS next 5Y	-
EPS past 3/5Y	-8.13% 32.87%
Sales past 3/5Y	- -
EPS Y/Y TTM	-28.83%
Sales Y/Y TTM	-
EPS Q/Q	2.57%
Sales Q/Q	-
Earnings	Aug 07 BMO
EPS/Sales Surpr.	7.32% -

Insider Own	1.52%
Insider Trans	0.00%
Inst Own	13.48%
Inst Trans	1.12%
ROA	-77.91%
ROE	-89.23%
ROIC	-140.55%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-4.57%
SMA50	-1.55%
SMA200	-40.27%
Trades

Shs Outstand	9.98M
Shs Float	9.83M
Short Float	6.95%
Short Ratio	9.63
Short Interest	0.68M
52W High	14.85 -83.84%
52W Low	1.70 41.18%
Volatility	9.84% 11.32%
ATR (14)	0.24
RSI (14)	47.42
Beta	1.41
Rel Volume	0.26
Avg Volume	70.97K
Volume	16,654

Perf Week	-5.14%
Perf Month	20.60%
Perf Quarter	9.59%
Perf Half Y	-54.55%
Perf YTD	-72.88%
Perf Year	-82.90%
Perf 3Y	-76.08%
Perf 5Y	-94.01%
Perf 10Y	-99.12%
Recom	1.00
Target Price	17.00
Prev Close	2.38
Price	2.40
Change %	0.84%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-26	Initiated	Rodman & Renshaw	Buy	$12
Jan-26-18	Initiated	Maxim Group	Buy	$2

Oct-19-26 08:00AM	Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today (PR Newswire) -12.03%
Oct-09-26 08:00AM	Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value (PR Newswire)
Sep-30-26 01:18PM	Atossa plans shareholder stake in potential PRV proceeds (Pharmaceutical Technology)
Sep-29-26 08:00AM	Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher (PR Newswire)
Sep-24-26 08:00AM	Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging (PR Newswire) -5.96%
08:45AM	Loading…
Aug-07-26 08:45AM	Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update (PR Newswire)
Jul-28-26 08:30AM	Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer (PR Newswire)
Jul-21-26 08:30AM	Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers (PR Newswire)
Jun-12-26 05:30PM	Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds (PR Newswire)
Jun-11-26 08:00AM	Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds (PR Newswire) -41.25%
Jun-10-26 12:51PM	Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment (Proactive)
May-27-26 08:30AM	Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial (PR Newswire)
May-20-26 04:45PM	Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy (PR Newswire)
May-14-26 08:30AM	Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer (PR Newswire)
May-08-26 08:45AM	Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update (PR Newswire)
08:30AM	Loading…
May-06-26 08:30AM	Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women (PR Newswire)
May-04-26 08:30AM	Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome (PR Newswire) +9.94%
Mar-25-26 05:30PM	Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update (PR Newswire) -13.10%
Mar-19-26 08:00AM	Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives (PR Newswire)
Mar-12-26 08:00AM	Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference (PR Newswire) +5.65%
Feb-11-26 08:30AM	Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook (PR Newswire) -15.98%
Feb-05-26 08:30AM	Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program (PR Newswire)
Jan-21-26 09:05AM	Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 (PR Newswire)
Jan-16-26 04:40PM	Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy (PR Newswire) +6.02%
Dec-17-25 08:15AM	Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category (PR Newswire)
Dec-15-25 08:00AM	Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium (PR Newswire) -13.37%
Dec-11-25 08:00AM	Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy (PR Newswire) +6.45%
Dec-09-25 08:00AM	Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen (PR Newswire)
Dec-04-25 08:00AM	Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum (PR Newswire)
Dec-02-25 08:00AM	Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma (PR Newswire) -5.65%
09:07AM	Loading…
Nov-17-25 09:07AM	Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation (PR Newswire)
Nov-12-25 08:15AM	Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (PR Newswire)
Nov-06-25 08:00AM	Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium (PR Newswire)
Oct-22-25 06:31AM	New Strong Sell Stocks for Oct. 22 (Zacks)
Oct-21-25 08:00AM	Atossa Therapeutics Highlights Progress in RECAST DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents (PR Newswire)
Oct-15-25 08:00AM	Atossa Therapeutics to Present at the Maxim Growth Summit 2025 (PR Newswire)
Oct-14-25 08:00AM	Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness (PR Newswire)
06:07AM	New Strong Sell Stocks for Oct. 14th (Zacks)
Oct-13-25 08:00AM	Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals (PR Newswire)
Oct-06-25 08:00AM	Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities (PR Newswire)
Oct-01-25 08:30AM	Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones (PR Newswire) +5.67%
Sep-17-25 08:00AM	Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services (GlobeNewswire)
Sep-08-25 08:30AM	Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction (PR Newswire)
Aug-28-25 08:30AM	Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference (PR Newswire)
Aug-20-25 08:30AM	Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer (PR Newswire)
Aug-12-25 08:30AM	Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update (PR Newswire)
Jul-29-25 07:45AM	Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer (PR Newswire) +13.14%
Jul-02-25 10:03PM	Ascendiant Lifts Atossa Therapeutics, Inc. (ATOS) Target Citing Strong Liquidity (Insider Monkey)
Jun-02-25 08:45AM	Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference (PR Newswire) +11.54%
May-20-25 09:00AM	Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 (ACCESSWIRE)
May-15-25 09:40AM	Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? (Zacks)
May-14-25 08:15AM	Atossa Therapeutics Announces Full Results from I-SPY?2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-Endoxifen (PR Newswire) +15.73%
May-13-25 08:00AM	Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update (PR Newswire) +6.34%
Apr-30-25 08:45AM	Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio (GlobeNewswire) +12.87%
Apr-29-25 08:45AM	Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 (GlobeNewswire) +7.09%
Apr-22-25 08:45AM	Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio (GlobeNewswire)
Apr-10-25 08:00AM	Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer (PR Newswire)
Mar-28-25 12:00PM	All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy (Zacks)
Mar-25-25 10:05AM	Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:00AM	Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-20-25 09:13AM	Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-11-25 08:15AM	Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications (GlobeNewswire)
Feb-05-25 08:00AM	Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care (GlobeNewswire)
Jan-30-25 08:17AM	Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 (GlobeNewswire)
Jan-23-25 08:15AM	Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 (GlobeNewswire)
Jan-06-25 09:00AM	Atossa Therapeutics Applauds U.S. Surgeon General's Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer (GlobeNewswire)
Dec-20-24 09:40AM	Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-13-24 08:20AM	Atossa Therapeutics to present poster on Z-endoxifen at SABCS (TipRanks)
Dec-12-24 08:15AM	Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -5.74%
Dec-11-24 08:15AM	Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density (GlobeNewswire)
Dec-10-24 09:05AM	Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-09-24 08:15AM	Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research (GlobeNewswire)
Nov-21-24 08:30AM	Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research (GlobeNewswire)
Nov-20-24 08:30AM	Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -6.25%
Nov-12-24 08:30AM	Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -7.41%
Nov-05-24 08:30AM	Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development (GlobeNewswire)
Nov-04-24 06:30AM	Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: (GlobeNewswire)
Oct-31-24 08:15AM	Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer (GlobeNewswire)
Oct-28-24 09:40AM	Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? (Zacks)
Oct-21-24 08:30AM	Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer (GlobeNewswire)
Oct-15-24 07:32AM	Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women (PR Newswire)
Oct-14-24 05:08PM	Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-01-24 08:30AM	Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum (GlobeNewswire)
Sep-19-24 09:40AM	Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-10-24 08:30AM	Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer (GlobeNewswire) +7.35%
Sep-03-24 09:40AM	Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? (Zacks)
08:30AM	Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-30-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice (Zacks)
Aug-28-24 08:30AM	Atossa Therapeutics Granted Additional Patent Protection for Endoxifen (GlobeNewswire)
Aug-21-24 11:30AM	Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer (GlobeNewswire)
Aug-20-24 08:30AM	Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations (GlobeNewswire)
Aug-12-24 08:30AM	Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.98%
Jul-22-24 08:30AM	Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer (GlobeNewswire) +10.45%
Jul-11-24 09:40AM	Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? (Zacks) +6.67%
07:00AM	3 Dirt-Cheap Drug Developers With Blockbuster Potential (InvestorPlace)
Jul-03-24 09:45AM	3 Penny Stock Moonshots with 300%+ Upside Potential by 2025 (InvestorPlace)
Jul-02-24 04:15PM	Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer (GlobeNewswire)
Jun-28-24 08:30AM	Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO ) in Women with ER+/HER2- Breast Cancer (GlobeNewswire)
Jun-17-24 08:30AM	Atossa Set to Join Russell 3000 Index Effective June 28, 2024 (GlobeNewswire)
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)

Show Previous News

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

M.D.Dr. Steven C. Quay FCAP

Chief Financial OfficerMr. Mark J. Daniel CPA

RACMs. Janet Rose Rea MSPH

Senior Vice President of Business OperationsMs. Delly Behen P.H.R.

Ph.D.Dr. Richard Graydon M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATOS

Atossa Therapeutics Inc

Upgrade your Finviz experience